NYSE:CNMD - CONMED Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $163.25
  • Forecasted Upside: 14.61 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$142.44
▲ +4.46 (3.23%)

This chart shows the closing price for CNMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CONMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNMD

Analyst Price Target is $163.25
▲ +14.61% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CONMED in the last 3 months. The average price target is $163.25, with a high forecast of $175.00 and a low forecast of $158.00. The average price target represents a 14.61% upside from the last price of $142.44.

This chart shows the closing price for CNMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in CONMED. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/15/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/13/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/12/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/28/2021Needham & Company LLCBoost Price TargetBuy$150.00 ➝ $158.00High
10/6/2021Needham & Company LLCUpgradeHold ➝ Buy$150.00High
7/15/2021UBS GroupInitiated CoverageBuy$160.00High
5/24/2021BarclaysInitiated CoverageOverweight$175.00Low
4/29/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$145.00 ➝ $160.00High
1/28/2021Piper SandlerBoost Price TargetOverweight$95.00 ➝ $145.00Low
7/30/2020Stifel NicolausBoost Price TargetBuy$82.00 ➝ $100.00High
7/30/2020SVB LeerinkBoost Price TargetMarket Perform$82.00 ➝ $92.00High
7/29/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $95.00Medium
4/30/2020SVB LeerinkReiterated RatingMarket PerformLow
4/30/2020Stifel NicolausBoost Price TargetBuy$65.00 ➝ $82.00Medium
4/30/2020Piper SandlerLower Price TargetOverweight$110.00 ➝ $90.00Medium
4/30/2020Needham & Company LLCReiterated RatingHoldMedium
4/23/2020JPMorgan Chase & Co.Lower Price TargetOverweight$136.00 ➝ $76.00Medium
4/14/2020BarclaysReiterated RatingBuy$110.00Medium
3/10/2020Piper SandlerLower Price Target$130.00 ➝ $110.00High
3/10/2020Needham & Company LLCReiterated RatingHoldHigh
11/26/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
11/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight$136.00Medium
10/31/2019Needham & Company LLCBoost Price TargetBuy$111.00 ➝ $115.00High
10/4/2019Needham & Company LLCBoost Price TargetBuy$101.00 ➝ $111.00Medium
8/22/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$88.00 ➝ $110.00High
8/1/2019Stifel NicolausBoost Price TargetBuy$97.00 ➝ $99.00High
8/1/2019BarclaysBoost Price TargetOverweight$96.00 ➝ $105.00High
4/17/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$95.00Medium
4/16/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$87.00 ➝ $94.00High
4/15/2019BarclaysBoost Price TargetOverweight ➝ Overweight$85.00 ➝ $92.00Low
2/27/2019Needham & Company LLCBoost Price TargetBuy$87.00Low
2/19/2019BarclaysInitiated CoverageEqual Weight ➝ Overweight$85.00High
1/23/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$86.00 ➝ $79.00High
10/16/2018BarclaysSet Price TargetEqual Weight ➝ Equal Weight$78.00High
8/30/2018SVB LeerinkBoost Price TargetMarket Perform$76.00 ➝ $81.00Low
8/2/2018Needham & Company LLCBoost Price TargetBuy$73.00 ➝ $83.00High
4/26/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$71.00 ➝ $73.00High
2/1/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$58.00 ➝ $71.00High
11/17/2017Needham & Company LLCReiterated RatingBuy$58.00N/A
11/3/2017KeyCorpReiterated RatingHoldN/A
11/3/2017Piper Jaffray CompaniesReiterated RatingHold$46.00N/A
9/1/2017Needham & Company LLCReiterated RatingBuy$57.00Low
8/25/2017KeyCorpReiterated RatingHoldLow
7/27/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$54.00 ➝ $57.00Low
4/27/2017LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$50.00 ➝ $48.00High
4/27/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$48.00 ➝ $54.00High
2/2/2017Needham & Company LLCReiterated RatingBuy$48.00N/A
(Data available from 12/7/2016 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2021
  • 4 very positive mentions
  • 8 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
8/9/2021
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/8/2021
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/8/2021
  • 7 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/7/2021
  • 4 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
12/7/2021

Current Sentiment

  • 4 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
CONMED logo
CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.
Read More

Today's Range

Now: $142.44
Low: $140.05
High: $144.84

50 Day Range

MA: $141.99
Low: $129.86
High: $157.03

52 Week Range

Now: $142.44
Low: $97.95
High: $159.11

Volume

301,084 shs

Average Volume

249,580 shs

Market Capitalization

$4.17 billion

P/E Ratio

71.22

Dividend Yield

0.58%

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of CONMED?

The following Wall Street sell-side analysts have issued research reports on CONMED in the last twelve months: Barclays PLC, Needham & Company LLC, Piper Sandler, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for CNMD.

What is the current price target for CONMED?

4 Wall Street analysts have set twelve-month price targets for CONMED in the last year. Their average twelve-month price target is $163.25, suggesting a possible upside of 18.3%. Barclays PLC has the highest price target set, predicting CNMD will reach $175.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $158.00 for CONMED in the next year.
View the latest price targets for CNMD.

What is the current consensus analyst rating for CONMED?

CONMED currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNMD will outperform the market and that investors should add to their positions of CONMED.
View the latest ratings for CNMD.

What other companies compete with CONMED?

How do I contact CONMED's investor relations team?

CONMED's physical mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The company's listed phone number is (727) 392-6464. The official website for CONMED is www.conmed.com.